Cancer Moonshotâ„  FY2023, FY2022, FY2021, FY2020, FY2019, FY2018, and FY2017 Funding Opportunities

Following the authorization of the 21st Century Cures Act, and the appropriation of $300 million in each fiscal year (FY) 2017 and FY 2018, NCI released the funding opportunity announcements (FOAs) listed below to high-priority research initiatives that align with the efforts of the Cancer Moonshot.

FY 2023 Closed FOAs
BRP Recommendation Title Announcement Number

Generation of Human Tumor Atlases

Request for Information (RFI) on Challenges and Opportunities Associated with Multidimensional Tumor Atlases

NOT-CA-23-011

FY 2022 Closed FOAs
BRP Recommendation Title Announcement Number
New Enabling Technologies Clinical Translation of Activated Optical Fluorescence Methods and Technologies for Sensitive Cancer Detection In Vivo (R01 Clinical Trial Optional) PAR-20-295
Human Tumor Atlas Network 3D Technologies to Accelerate HTAN Atlas Building Efforts (UH2 Clinical Trial Not Allowed) RFA-CA-21-037
FY 2021 Closed FOAs
BRP Recommendation Title Announcement Number
Direct Patient Engagement Network Patient Engagement and Cancer Genome Sequencing (PE-CGS): Research Centers (U2C Clinical Trial Optional) RFA-CA-19-045
National Cancer Data Ecosystem Visualization Methods and Tools Development for Enhancing Cancer Moonshot Data (R33 Clinical Trial Not Allowed) RFA-CA-20-044
Human Tumor Atlas Network 3D Technologies to Accelerate HTAN Atlas Building Efforts (UH2 Clinical Trial Not Allowed) RFA-CA-20-042
Therapeutic Target Identification to Overcome Resistance Revision Applications for Mechanisms of Cancer Drug Resistance (R01 Clinical Trial Not Allowed) RFA-CA-19-049
Pediatric Immunotherapy Network Request for Information (RFI): Input for National Cancer Institute (NCI) Pediatric Immunotherapy Network NOT-CA-21-086
Adult Immunotherapy Network Notice of Special Interest: Administrative Supplements for Cancer Moonshot awardees and Cancer Center Support Grants (CCSG) to Support Development of an "Immune Radiation Response Index (i-RRI)" for Immune Cells from Normal and Tumor Microenvironments NOT-CA-21-083
FY 2020 Closed FOAs
BRP Recommendation Title Announcement Number
Direct Patient Engagement Network  Patient Engagement and Cancer Genome Sequencing (PE-CGS): Coordinating Center (U24 Clinical Trial Not Allowed) RFA-CA-19-046
Drug Resistance Network Notice of Special Interest (NOSI): Administrative Supplements to Support Collaborations with the NCI-supported Drug Resistance and Sensitivity Network (DRSN) NOT-CA-20-014
FY 2019 Closed FOAs
BRP Recommendation Title Announcement Number
New Enabling Technologies Novel Technology Tools to Facilitate Research Using Next Generation Patient-derived Cancer Models (U01 Clinical Trial Not Allowed) RFA-CA-19-055
Prevention and Early Detection: Implementation Science Approaches to Identify and Care for Individuals with Inherited Cancer Syndromes (U01) RFA-CA-19-017
Prevention and Early Detection: Implementation Science Communication and Decision Making for Individuals with Inherited Cancer Syndromes (U01) RFA-CA-19-001
Prevention and Early Detection: Implementation Science Implementation Science for Cancer Control: Developing Centers (P50 Clinical Trial Optional) RFA-CA-19-005
Prevention and Early Detection: Implementation Science Implementation Science for Cancer Control: Advanced Centers (P50 Clinical Trial Optional) RFA-CA-19-006
Cancer Immunotherapy Translational Science Network Immuno-Oncology Translation Network (IOTN): Cancer Immunoprevention Research Projects (UG3/UH3 Clinical Trials Not Allowed) RFA-CA-19-012
Cancer Immunotherapy Translational Science Network Immuno-Oncology Translation Network (IOTN): Immuno-engineering to Improve Immunotherapy (i3) Centers (U54 Clinical Trial Not Allowed) RFA-CA-19-013
Cancer Immunotherapy Translational Science Network Immuno-Oncology Translation Network (IOTN): Cancer Immunoprevention Research Projects (U01 Clinical Trial Not Allowed) RFA-CA-19-014
Cancer Immunotherapy Translational Science Network Immuno-Oncology Translation Network (IOTN): Cancer Immunotherapy Research Projects (U01 Clinical Trial Not Allowed) RFA-CA-19-015
Prevention and Early Detection: Implementation Science Accelerating Colorectal Cancer Screening and follow-up through Implementation Science (ACCSIS, Second Wave) (UG3/UH3 Clinical Trial Required) RFA-CA-19-018
Therapeutic Target Identification to Overcome Resistance Notice of Special Interest: Administrative Supplements to Support Collaborations with the Drug Resistance and Sensitivity Network (DRSN) NOT-CA-19-032
New Enabling Technologies Administrative Supplements to NCI Grant and Cooperative Agreement Awards to Support Collaborations with the PDX Development and Trial Centers Research Network (PDXNet) (Admin Supp Clinical Trial Not Allowed) PA-19-174
Cancer Immunotherapy Translational Science Network Advancing Cancer Immunotherapy by Mitigating Immune-Related Adverse Events (irAE) (U01 Clinical Trial Not Allowed) RFA-CA-19-044
Cancer Immunotherapy Translational Science Network Notice of Special Interest: Administrative Supplements for Activities to Promote Human Immune-Representing Oncology Models     NOT-CA-19-028
New Enabling Cancer Technologies Spatial Sequencing Technologies with Single Cell Resolution for Cancer Research PHS 2020-1/Topic 403
New Enabling Cancer Technologies Subcellular Microscopy and -Omics in Cancer Cell Biology PHS 2020-1/Topic 404 
New Enabling Cancer Technologies Intra-Tumor Sensing Technologies for Tumor Pharmacotyping PHS 2020-1/Topic 405
Prevention and Early Detection Software for Patient Navigation Through the Cancer Care Continuum PHS 2020-1/Topic 406
National Cancer Data Ecosystem Cloud-Based Software for the Cancer Research Data Commons PHS 2020-1/Topic 407
Generation of Human Tumor Atlases Tools and Technologies for Visualizing Multi-Scale Data PHS 2020-1/Topic 408
Network for Patient Engagement Cancer Clinical Trials Recruitment and Retention Tools for Participant Engagement PHS 2020-1/Topic 410
Symptom Management Research Software Enabling Data Integration from Wearable Sensors for Cancer Patients PHS 2020-1/Topic 412
Cancer Immunotherapy Translational Science Network Pediatric Immunotherapy-Discovery and Development Network (PI-DDN) (U54) RFA-CA-19-003
Cancer Immunotherapy Translational Science Network Pediatric Immunotherapy- Discovery and Development Network (PI-DDN) (U01) RFA-CA-19-004
Drivers of Childhood Cancers Fusion Oncoproteins in Childhood Cancers (FusOnC2) Consortium (U54) RFA-CA-19-016
FY 2018 Closed FOAs
BRP Recommendation Title Announcement Number
Adult Immunotherapy Translational Science Network Immuno-Oncology Translation Network (IOTN): CIDR (U24) RFA-CA-17-048
Adult Immunotherapy Translational Science Network Immuno-Oncology Translation Network (IOTN): DMRC (U24) RFA-CA-17-047
Adult Immunotherapy Translational Science Network Immuno-Oncology Translation Network (IOTN): Cancer Immunoprevention (U01) RFA-CA-17-046
Adult Immunotherapy Translational Science Network Development and Validation of Non-Mouse Reagents to Enable Preclinical Development of Novel Therapeutics (R43/44) PHS2018-1/Topic 372
Adult Immunotherapy Translational Science Network Immuno-Oncology Translation Network (IOTN): Cancer Immunotherapy (U01) RFA-CA-17-045
Pediatric Immunotherapy Translational Science Network Pediatric Immunotherapy Discovery and Development Network (PI-DDN) (U01) RFA-CA-17-051
Pediatric Immunotherapy Translational Science Network Pediatric Immunotherapy Discovery and Development Network (PI-DDN) (U54) RFA-CA-17-050
Drivers of Childhood Cancers Fusion Oncoproteins in Childhood Cancers (FusOnC2) Consortium (U54) RFA-CA-17-049
Generation of Human Tumor Atlases Human Tumor Atlas Network: Data Coordinating Center (U24) RFA-CA-17-036
Generation of Human Tumor Atlases Pre-Cancer Atlas (PCA) Research Centers (U2C) RFA-CA-17-035
Generation of Human Tumor Atlases Imaging-Based Tools for Longitudinal and Multi-Dimensional Mapping of the Tumor and its Microenvironment (R43/R44) PHS2018-1/Topic 376
Generation of Human Tumor Atlases Human Tumor Atlas Research Centers (U2C) RFA-CA-17-034
Hereditary Cancers Approaches to Identify & Care for Individuals w/ Inherited Cancer Syndromes (U01) RFA-CA-17-041
Prevention and Screening ACCSIS: Coordinating Center (U24) RFA-CA-17-039
Prevention and Screening ACCSIS (UG3/UH3) RFA-CA-17-038
Symptom Management Research Analyzing & Interpreting Clinician & Patient Adverse Event Data to Understand Tolerability (U01) RFA-CA-17-052
Symptom Management Research Coordinating Center for Research Centers for Improving Management of Symptoms (U24) RFA-CA-17-043
Symptom Management Research Bridging the Guideline Implementation Gap: Clinical Decision-Support to Improve Cancer Symptom Management (R43/R44) PHS2018-1/Topic 377
Symptom Management Research Software Enabling Data Integration from Wearable Sensors to Generate Novel Analytics for Cancer Patients (R43/R44) PHS2018-1/Topic 379
Symptom Management Research Research Centers for Improving Management of Symptoms (UM1) RFA-CA-17-042
Therapeutic Target Identification to Overcome Resistance Mechanisms of Cancer Drug Resistance and Sensitivity: Coordinating Center (U24) RFA-CA-17-044
New Enabling Technologies Minority Patient-Derived Xenograft (PDX) Development and Trial Centers (M-PDTCs) (U54) RFA-CA-17-032
New Enabling Technologies Supplements to Support Collaborations with the PDXNet (Admin Supp) PA-18-496
New Enabling Technologies Diagnostic Imaging for Cancer Immunotherapies (R43/R44) PHS2018-1/Topic 375
New Enabling Technologies Tools and Technologies for Monitoring RNA Modifications (R43) PHS2018-1/Topic 373
New Enabling Technologies Computer Aided Decision Support for Radiation Oncology (R43/R44) PHS2018-1/Topic 380
Drivers of Childhood Cancers APRC on Fusion Oncoproteins as Drivers of Childhood Cancer (Admin Supp) PA-17-138
New Enabling Technologies APTRC for Cancer Research (Admin Supp) PA-17-143
Prevention and Early Detection: Implementation Science Improving Smoking Cessation in Socioeconomically Disadvantaged Populations via Scalable Interventions (R01) PAR-16-202
Prevention and Early Detection: Implementation Science Improving Smoking Cessation in Socioeconomically Disadvantaged Populations via Scalable Interventions (R21) PAR-16-201
Prevention and Early Detection: Implementation Science Dissemination and Implementation Research in Health (R21) PAR-16-236
Prevention and Early Detection: Implementation Science Dissemination and Implementation Research in Health (R01) PAR-16-238
FY 2017 Closed FOAs
BRP Recommendation Title Announcement Number
Adult Immunotherapy Translational Science Network Canine Immunotherapy Trials and Correlative Studies (U01) RFA-CA-17-001
Adult Immunotherapy Translational Science Network Coordinating Center for Canine Immunotherapy Trials and Correlative Studies (U24) RFA-CA-17-002
Adult Immunotherapy Translational Science Network Consortium for PDAC Translational Studies on the Tumor Microenvironment (U01) RFA-CA-17-015
Adult Immunotherapy Translational Science Network Resource Center for the Consortium for PDAC Translational Studies (U24) RFA-CA-17-016
Adult Immunotherapy Translational Science Network Cancer Immune Monitoring and Analysis Centers (CIMACs) (U24) RFA-CA-17-005
Adult Immunotherapy Translational Science Network Cancer Immunologic Data Common (CIDC) (U24) RFA-CA-17-006
Adult Immunotherapy Translational Science Network Limited Competition: Cancer Immunotherapy Trials Network (CITN) (UM1) RFA-CA-16-501
Adult Immunotherapy Translational Science Network APRC-irAEs Associated with Cancer Immunotherapy (Admin Supp) PA-17-248
New Enabling Technologies PDX Development and Trial Centers (PDTCs) (U54) RFA-CA-17-003
New Enabling Technologies PDX Data Commons and Coordinating Center (PDCCC) for the PDXNet (U24) RFA-CA-17-004
New Enabling Technologies Integration and Validation of Emerging Technologies to Accelerate Cancer Research (R33) RFA-CA-17-023
Therapeutic Target Identification to Overcome Resistance Mechanisms of Cancer Drug Resistance and Sensitivity (U54) RFA-CA-17-009